Physician profile
Mark Wilson
NPI 1184612368
$2,376.85
in general payments reported to CMS, 2019-2025
25 companies · $524 in 2025
The $524 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $99.01 · 2021: $409 · 2022: $451 · 2023: $335 · 2024: $320 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,178.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $520.97 | 2019-2025 | Creon, Rinvoq, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $451.89 | 2019-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $297.84 | 2019-2025 | Entyvio, Gattex |
| Phathom Pharmaceuticals, INC. | $200.75 | 2023-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $153.14 | 2022-2025 | Dupixent |
| Mauna Kea Technologies, INC. | $108.81 | 2021 | |
| Celgene Corporation | $106.35 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $94.06 | 2019-2024 | Linzess |
| Merck Sharp & Dohme LLC | $61.04 | 2023-2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $53.92 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $43.71 | 2022-2023 | Suflave, Sutab |
| Janssen Biotech, INC. | $36.91 | 2019-2025 | Tremfya |
| Ardelyx, INC. | $35.97 | 2023-2024 | Ibsrela |
| Fujifilm Healthcare Americas Corporation | $33.91 | 2020 | |
| Genzyme Corporation | $31.48 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $23.49 | 2025 | Sucraid |
| Boston Scientific Corporation | $20.69 | 2023 | |
| Novo Nordisk INC | $16.60 | 2025 | Saxenda, Wegovy |
| Pharmacosmos Therapeutics INC. | $15.71 | 2021 | |
| Intercept Pharmaceuticals, INC. | $15.61 | 2025 | |
| Madrigal Pharmaceuticals | $14.61 | 2025 | Rezdiffra |
| Redhill Biopharma INC. | $14.46 | 2023 | Talicia, Aemcolo, Movantik |
| Alexion Pharmaceuticals, INC. | $13.08 | 2022 | |
| Shire North American Group INC | $11.85 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$42,382.80 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.